Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masayoshi Harigai

Showing results (21-30 of 309) with videos related to

Pageof 31
Sort By:
International Journal of Rheumatic Diseases|October 5, 2020
Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the National Database of Health Insurance Claims and Specific Health Checkups of JapanAyako Nakajima, Ryoko Sakai, Eisuke Inoue, et al.
The Korean Journal of Internal Medicine|January 8, 2019
Molecular targeted therapies for microscopic polyangiitis and granulomatosis with polyangiitisMasayoshi Harigai, Michi Tsutsumino, Hideto Takada, et al.
Modern Rheumatology|April 8, 2017
Long-term safety and effectiveness of adalimumab for the treatment of Japanese patients with rheumatoid arthritis: 3-year results from a postmarketing surveillance of 552 patientsMasayoshi Harigai, Tsuyoshi Tsuchiya, Katsuyoshi Kawana, et al.
Lupus|April 9, 2020
Serum levels of soluble programmed cell death protein 1 and soluble programmed cell death protein ligand 2 are increased in systemic lupus erythematosus and associated with the disease activityShinya Hirahara, Yasuhiro Katsumata, Hidenaga Kawasumi, et al.
International Journal of Rheumatic Diseases|April 30, 2016
Tacrolimus successfully used to control refractory eosinophilic granulomatosis with polyangiitis complicated by invasive aspergillosis and chronic hepatitis BFumio Hirano, Fumitaka Mizoguchi, Masayoshi Harigai, et al.
Psychoneuroendocrinology|February 12, 2008
Blood-brain barrier damage as a risk factor for corticosteroid-induced psychiatric disorders in systemic lupus erythematosusKatsuji Nishimura, Masayoshi Harigai, Masako Omori, et al.
Modern Rheumatology|November 23, 2013
A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapyMasayoshi Harigai, Satoshi Mochida, Toshihide Mimura, et al.
Modern Rheumatology|December 15, 2021
Long-term safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis: 3-year follow-up of a postmarketing surveillanceMasayoshi Harigai, Katsuki Tsuritani, Yuri Yoshizawa, et al.
Journal of Medical and Dental Sciences|May 26, 2006
Fundamental data quality assessments of clinical trials in JapanHajime Saijo, Hiroi Kasai, Hiromitu Takahashi, et al.
Modern Rheumatology|May 15, 2026
Medical pre-training and fine-tuning improve large-language-model prediction of rheumatoid-arthritis disease activitySuguru Honda, Katsunori Ikari, Mayuko Fujisaki, et al.
Pageof 31

Showing results (21-30 of 309) with videos related to

Sort By:
Pageof 31
International Journal of Rheumatic Diseases|October 5, 2020
Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the National Database of Health Insurance Claims and Specific Health Checkups of JapanAyako Nakajima, Ryoko Sakai, Eisuke Inoue, et al.
The Korean Journal of Internal Medicine|January 8, 2019
Molecular targeted therapies for microscopic polyangiitis and granulomatosis with polyangiitisMasayoshi Harigai, Michi Tsutsumino, Hideto Takada, et al.
Modern Rheumatology|April 8, 2017
Long-term safety and effectiveness of adalimumab for the treatment of Japanese patients with rheumatoid arthritis: 3-year results from a postmarketing surveillance of 552 patientsMasayoshi Harigai, Tsuyoshi Tsuchiya, Katsuyoshi Kawana, et al.
Lupus|April 9, 2020
Serum levels of soluble programmed cell death protein 1 and soluble programmed cell death protein ligand 2 are increased in systemic lupus erythematosus and associated with the disease activityShinya Hirahara, Yasuhiro Katsumata, Hidenaga Kawasumi, et al.
International Journal of Rheumatic Diseases|April 30, 2016
Tacrolimus successfully used to control refractory eosinophilic granulomatosis with polyangiitis complicated by invasive aspergillosis and chronic hepatitis BFumio Hirano, Fumitaka Mizoguchi, Masayoshi Harigai, et al.
Psychoneuroendocrinology|February 12, 2008
Blood-brain barrier damage as a risk factor for corticosteroid-induced psychiatric disorders in systemic lupus erythematosusKatsuji Nishimura, Masayoshi Harigai, Masako Omori, et al.
Modern Rheumatology|November 23, 2013
A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapyMasayoshi Harigai, Satoshi Mochida, Toshihide Mimura, et al.
Modern Rheumatology|December 15, 2021
Long-term safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis: 3-year follow-up of a postmarketing surveillanceMasayoshi Harigai, Katsuki Tsuritani, Yuri Yoshizawa, et al.
Journal of Medical and Dental Sciences|May 26, 2006
Fundamental data quality assessments of clinical trials in JapanHajime Saijo, Hiroi Kasai, Hiromitu Takahashi, et al.
Modern Rheumatology|May 15, 2026
Medical pre-training and fine-tuning improve large-language-model prediction of rheumatoid-arthritis disease activitySuguru Honda, Katsunori Ikari, Mayuko Fujisaki, et al.
Pageof 31